Zagotenemab
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
0
Recruiting
0
Completed
3
Sites
72
Countries
4
Endpoints
36
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 36 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 10 of 36 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
2
2
2
2
2
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT03518073A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease | Zagotenemab Alzheimer’s disease | Age 60-85 | Ph 2 | Completed | 60 | Aug 2021 | 1 | results |
| NCT03019536A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease | Zagotenemab Alzheimer’s disease, MCI / preclinical Alzheimer’s | mild-to-moderate AD | Ph 1 | Completed | 11 | Jun 2019 | 1 | results |
| NCT02754830A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD) | Zagotenemab Alzheimer’s disease, MCI / preclinical Alzheimer’s | MCI due to AD / mild-to-moderate AD | Ph 1 | Completed | 2 | Jul 2018 | - | results |
Showing 1-3 of 3 trials